CatalystMarker
← board

SIGA

SIGA Technologiesdistress 1/10 · well-funded / low risk
$3.30-3%today-65% from 52w high
siga.com49 employeesFounded 1995New York, NYDrug Manufacturers - Specialty & Generic
Lead: Smallpox
Revenue
pre-revenue
Liquidity
$146M
Runway
—
Shares 1y
+0%

Price & events

-44.6% over 6M
$3.30$4.72$6.15Jan 26Apr 26Jul 262.0M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-7.3%
1W
-23.3%
1M
-27.2%
3M
-43.8%
6M
-47.9%
1Y
-57.3%
2Y
-15.8%
5Y
-29.8%
All

Overview

Market Cap
$236.69M
Volume
41.49K
52 Week Range
$3.30 – $9.48
Total Shares
71.72M
Float Shares
41.01M
Short %
7.47%
% Held by Insiders
42.80%
% Held by Institutions
49.84%
RVOL
0.07x
Beta
0.89

Pipeline stages · 1 programs

Tecovirimat, Smallpox and Mpox Vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2027-01-01

Pipeline · 1 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2027-01-01
Estimated 50%
readout ~2027-02-15
Phase 2Tecovirimat, Smallpox and Mpox VaccineSmallpox—active not recruiting

Catalyst news & presentations · 1

Approved drugs (2)

  • TPOXXTECOVIRIMAT2022 · Prescription
  • TPOXXTECOVIRIMAT2018 · Prescription

Capital structure — dilution & financing

Shares out: 71,724,097 · 0 offerings/1y · 0 PIPEs
  • 2024-11-08SC 13Gstrategic_stake
  • 2024-10-24SC 13Gstrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — Smallpox

  • BNTXBioNTech SE$23.1B · D1

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.